

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
Biocon Biologics Inc.	83257002042	Adalimumab fkjp 20 mg/0.4 mL PFS	5/27/2024

<b>Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally</b>	<b>The estimated volume of patients who may be prescribed the drug</b>
<p>This is a new NDC for a product acquired by Biocon in November 2022. With this new NDC launch, Biocon is not changing the WAC price. Biocon approaches drug pricing decisions by considering several crucial factors. These include manufacturing complexities, research and development time and investments, patient demographics and access, and focused understanding of the regulatory framework governing sales to government and institutional entities.</p>	<p>5500000</p>

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Date and price of acquisition if the drug was not developed by the manufacturer
N	11/29/2022 for \$3 Billion for the full portfolio of Viatris biosimilar products